Celera Genomics

(CRA)

reported a narrower-than-expected first-quarter loss as revenue for the company that's mapping the human genome more than doubled.

The genomics technology company posted a loss of $25.7 million, or 43 cents a share, compared with a loss of $19.4 million, or 38 cents a share, in the year-ago period. Analysts expected the company to lose 57 cents a share, according to an

I/B/E/S

TST Recommends

survey.

Revenue for the quarter rose to $18.3 million from $8.3 million last year, fueled by an increase in subscription agreements. Celera is a unit of

PE Corp.

Shares of Celera recently gained $3.38, or 5.1%, to $69 in

New York Stock Exchange

composite trading.